Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Bevacizumab + Paclitaxel + Pembrolizumab/berahyaluronidase alfa & Ovarian Cancer, on February 10, 2026, the Food and Drug Administration (FDA) approved Bevacizumab + Paclitaxel + Pembrolizumab/berahyaluronidase alfa for the treatment of adult patients with Ovarian cancer. The approval is specifically for tumors that express PD-L1 with a Combined Positive Score (CPS) of 1 or greater, as determined by the FDA approved PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Inc) companion diagnostic device. Eligible patients are those who have undergone one or two prior systemic treatment regimens.…